Post

New research · Ophthalmology
Journal of clinical medicine · 5d
ReviewJournal of clinical medicine · 2026

Nose-to-Eye Delivery: The Potential of Intranasal Administration in Ophthalmology.

Maria Letizia Adezio, Danilo Iannetta, Gianluca Manni … Ludovico Alisi
Read paper
OphthalmologyReview

Conventional eye drops provide very low drug delivery to the eye.

Nose-to-Eye Delivery: The Potential of Intranasal Administration in Ophthalmology.

Maria Letizia Adezio … Ludovico Alisi
Journal of clinical medicine · 2026
Purpose

This review explores the intranasal (intranasal) route as a promising strategy for targeting both the anterior and posterior segments of the eye.

less than 5%
Results
less than 5%
very little medicine from eye drops actually reaches the eye
More results

Pre-clinical evidence indicates that intranasal administration of agents such as erythropoietin, nerve growth factor, and insulin achieves superior retinal concentrations compared to topical or systemic dosing, offering neuroprotection in models of retinal degeneration and glaucoma.

“
Conclusion

Future advancements in mucoadhesive nanocarriers are essential to optimize drug residence time and realize the full potential of nose-to-eye delivery in chronic ophthalmic care.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving